SPECIAL BULLETIN COVID-19 #235: New ICD-10 Diagnosis and Procedure Codes Effective April 1, 2022
CDC implementing twelve new codes; now available in NCTracks

CDC implementing twelve new codes; now available in NCTracks

In response to the ongoing COVID-19 public health emergency, the Centers for Disease Control and Prevention’s (CDC) National Center for Health Statistics (NCHS) is implementing three new diagnosis codes into the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) for reporting COVID-19 vaccination status, effective April 1, 2022.



Diagnosis Code


Description


Z28.310


Unvaccinated for COVID-19


Z28.311


Partially vaccinated for COVID-19


Z28.39


Other underimmunization status

In response to the ongoing COVID-19 public health emergency, the Centers for Medicare & Medicaid Services (CMS) is implementing nine new procedure codes, to describe the introduction or infusion of therapeutics, including vaccines for COVID-19 treatment, into the International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), effective April 1, 2022.



Procedure Code


Description


XW013V7


Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7


XW013W7


Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7


XW023V7


Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7


XW023W7


Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7


XW0DXR7


Introduction of Fostamatinib into Mouth and Pharynx, External Approach, New Technology Group 7


XW0G7R7


Introduction of Fostamatinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 7


XW0H7R7


Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7


XW023X7


Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7


XW023Y7


Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7

These codes are available in NCTracks and providers may bill the codes effective with dates of service on or after April 1, 2022.

CONTACT

NCTracks Contact Center: 800-688-6696

 

 

Related Topics: